Ocorrência de carcinoma espinocelular labial não melanocítico em usuários crônicos de hidroclorotiazida
DOI:
https://doi.org/10.5335/rfo.v27i1.14222Palavras-chave:
Agentes fotossensibilizantes. Hidroclorotiazida. Câncer de Boca. Carcinoma Espinocelular. Anti-hipertensivos.Resumo
Introdução: Diversos autores desenvolveram estudos acerca da potencial associação entre a etiocarcinogênese do carcinoma espinocelular não melanocítico (CECNM) labial e o uso crônico da hidroclorotiazida (HCTZ). Objetivo: A atual revisão objetivou investigar a relação do diurético HCTZ e o risco de CECNM labial. Métodos: Realizou-se uma revisão de literatura nas bases de dados LILACS, PUBMED/MEDLINE e Periódico CAPES, em que foram incluídos artigos em inglês, português e francês, publicados no período de 2017 a 2022. Foram propostos 60 documentos e, dentre esses, 30 foram selecionados para compor a amostra no estudo. Resultados: Foi evidenciada uma relação entre o uso da HCTZ e a ocorrência de CECNM com relação dose cumulativa devido às alterações provocadas pelo fármaco, no entanto, em virtude da heterogeneidade de desenhos metodológicos e concentração dos estudos em populações semelhantes, existem limitações quanto à confiabilidade dessas informações. Conclusão: Identificou-se uma desproporção entre a ocorrência e relevância do CECNM e a produção científica vigente, demonstrando a necessidade de estudos com metodologias padronizadas que abranjam diferentes especificidades socioeconômicas e demográficas.
Downloads
Os dados de download ainda não estão disponíveis.
Referências
1. Damps T, Czuwara J, Warszawik-Hendzel O, Misicka A, Rudnicka L. The role of drugs and selected dietary factors in cutaneous squamous cell carcinogenesis. Postepy Dermatol Alergol. 202;38(2):198-204.
2. Garrido PM e Costa JB. Terapêutica com hidroclorotiazida e risco de cancro cutâneo não melanoma: revisão da literatura. Rev Port Cardiol. 2019;39(3):163-170.
3. Korzeniowska K, Cieślewicz A, Chmara E, Jabłecka A, Pawlaczyk M. Photosensitivity reactions in the elderly population: questionnaire-based survey and literature review. Ther Clin Risk Manag. 2019;15:1111-1119.
4. Llamas-Molina JM, Navarro-Triviño FJ, Ruiz-Villaverde R. What Dermatologists Should Know About Thiazides. Actas Dermosifiliogr. 2022;113(5):498-504.
5. Bendinelli B, Masala G, Garamella G, Palli D, Caini S. Do thiazide diuretics increase the risk of skin cancer? A critical review of the scientific evidence and updated meta-analysis. Curr Cardiol Rep. 2019;21(9):92.
6. A.C. Camargo Cancer Center. Pele Não Melanoma. Disponível em: https://www.accamargo.org.br/sobre-o-cancer/tipos-de-cancer/pele-nao-melanoma. Acesso em: 05, jul, 2022.
7. Andrade KVF e Souza AM. Prevalência de interações medicamentosas potenciais em indivíduos hipertensos acompanhados na estratégia de saúde da família. J Biol Sci. 2018;6(4):405-411.
8. Lee SM, Kim K, Yoon J, Park SK, Moon S, Lee SE, et al. Association between hydrochlorothiazide use and risk of non-melanoma skin cancer: cohort study of the common data model in the Asian population. J Clin Med. 2020;9(9):2910.
9. Shin D, Lee ES, Kim J, Guerra L, Naik D, Prida X. Association Between the Use of Thiazide Diuretics and the Risk of Skin Cancers: A Meta-Analysis of Observational Studies. J Clin Med Res. 2019;11(4):247-255.
10. Warszawik-Hendzel O, Olszewska M, Rakowska A, Sikora M, Hendzel P, Rudnicka L. Cardiovascular Drug Use and Risk of Actinic Keratosis: A Case-Control Study. Dermatol Ther (Heidelb). 2020;10(4):735-743.
11. Bigagli E, Cinci L, D’ambrosio M, Nardini P, Portelli F, Colucci R, et al. Hydrochlorothiazide Use and Risk of Nonmelanoma Skin Cancers: A Biological Plausibility Study. Oxid Med Cell Longev. 2021;2021:6655542.
12. O’neill B, Moe S, Korownyk C. Hydrochlorothiazide and squamous cell carcinoma. Can Fam Physician. 2020;66(2):116-116.
13. Drucker AM, Hollestein L, Na Y, Weinstock MA, Li WQ, Abdel Qadir HA, et al. Association between antihypertensive medications and risk of skin cancer in people older than 65 years: a population-based study. CMAJ. 2021;193(15):508-516.
14. Perdersen SA, Gaist D, Schimidt SAJ, Hölmich LR, Friis S, Pottegård A. Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark. J Am Acad Dermatol. 2018;78(4):673-681.
15. Borges JES, Camelier AA, Oliveira LVF, Brandão GS Qualidade de vida de idosos hipertensos e diabéticos da comunidade: um estudo observacional. Rev Pesqui Fisioter. 2019;9(1):74-84.
16. Dias JRP, Andrade RL, Fernandes ANM, Laurindo BM, Fonseca ERS. Análise do perfil clínico-epidemiológico dos idosos portadores de hipertensão arterial sistêmica nas microáreas 4, 6 e 7 da USF tenoné. BJHR. 2019;2(1):2-41.
17. Kim H, Ihm S, Kim G, Kim J, Kim K, Lee H, et al. Korean Society of Hypertension guidelines for the management of hypertension: part I-epidemiology of hypertension. Clin Exp Hypertens. 2019;25:1-16 – A.
18. Kim H, Ihm S, Kim G, Kim J, Kim K, Lee H, et al. Korean Society of Hypertension guidelines for the management of hypertension: part III-hypertension in special situations. Clin Exp Hypertens. 2019;25:1-16 – B.
19. Lee H, Shin J, Kim G, Park S, Ihm S, Kim H, et al. Korean Society of Hypertension Guidelines for the management of hypertension: part II-diagnosis and treatment of hypertension. Clin Exp Hypertens. 2019;25:20.
20. Kreutz R, Algharably EAH, Douros, A. Reviewing the effects of thiazide and thiazide-like diuretics as photosensitizing drugs on the risk of skin cancer. J Hypertens. 2019;37(10):1950-1958.
21. Su KA, Habel LA, Achacoso NS, Friedman GD, Agasri MM. Photosensitizing antihypertensive drug use and risk of cutaneous squamous cell carcinoma. Br J Dermatol. 2018;179(5):1088-1094.
22. Montgomery S e Scott W. Photosensitizing Drug Reactions. Clin Dermatol. 2022 Jan-Feb;40(1):57-63.
23. Mehlan J, Ueberschaar J, Hagenström K, Garbe C, Spitzer MS, Druchkiv V, Schuettauf F. The use of HCT and/or ACE inhibitors significantly increases the risk of non-melanotic skin cancer in the periocular region. Graefes Arch Clin Exp Ophthalmol. 2022;260(8):2745-2751.
24. Rouette J, Yin H, Pottegård A, Nirantharakumar K, Azoulay L. Use of Hydrochlorothiazide and Risk of Melanoma and Nonmelanoma Skin Cancer. Drug Saf. 2021;44(2):245-254.
25. Schneider R, Reinau D, Stoffel S, Jick SS, Meier CR, Spoendlin J. Risk of skin cancer in new users of thiazides and thiazide-like diuretics: a cohort study using an active comparator group. Br J Dermatol. 2021;185(2):343-352.
26. Eworuke E, Haug N, Bradley M, Cosgrove A, Zhang T, Dee EC, et al. Risk of Nonmelanoma Skin Cancer in Association With Use of Hydrochlorothiazide-Containing Products in the United States. JNCI Cancer Spectr. 2021;5(2).
27. Pottegard A, Hallas J, Olesen M, Svendsen MT, Habel LA, Friedman GD, Friis S. Hydrochlorithiazide use is strongly associated with risk of lip cancer. J Intern Med. 2017;282(4):322-331.
28. Morales DR, Pacurariu A, Slattery J, Kurz X. Association between hydrochlorothiazide exposure and different incident skin, lip and oral cavity cancers. Br J Clin Pharmacol. 2020;86(7):1336-1345.
29. Park E, Lee Y, Jue MS. Hydrochlorothiazide use and the risk of skin cancer in patients with hypertensive disorder: a nationwide retrospective cohort study from Korea. Korean J Intern Med. 2020;35(4):917-928.
30. Pottegard A, Pedersen SA, Schmidt SAJ, Lee CN, Hsu CK, Liao TC, et al. Hydrochlorithiazide use and skin cancer risk: a Taiwanese national case-control study. Br J Cancer. 2019;121(11):973-978.
2. Garrido PM e Costa JB. Terapêutica com hidroclorotiazida e risco de cancro cutâneo não melanoma: revisão da literatura. Rev Port Cardiol. 2019;39(3):163-170.
3. Korzeniowska K, Cieślewicz A, Chmara E, Jabłecka A, Pawlaczyk M. Photosensitivity reactions in the elderly population: questionnaire-based survey and literature review. Ther Clin Risk Manag. 2019;15:1111-1119.
4. Llamas-Molina JM, Navarro-Triviño FJ, Ruiz-Villaverde R. What Dermatologists Should Know About Thiazides. Actas Dermosifiliogr. 2022;113(5):498-504.
5. Bendinelli B, Masala G, Garamella G, Palli D, Caini S. Do thiazide diuretics increase the risk of skin cancer? A critical review of the scientific evidence and updated meta-analysis. Curr Cardiol Rep. 2019;21(9):92.
6. A.C. Camargo Cancer Center. Pele Não Melanoma. Disponível em: https://www.accamargo.org.br/sobre-o-cancer/tipos-de-cancer/pele-nao-melanoma. Acesso em: 05, jul, 2022.
7. Andrade KVF e Souza AM. Prevalência de interações medicamentosas potenciais em indivíduos hipertensos acompanhados na estratégia de saúde da família. J Biol Sci. 2018;6(4):405-411.
8. Lee SM, Kim K, Yoon J, Park SK, Moon S, Lee SE, et al. Association between hydrochlorothiazide use and risk of non-melanoma skin cancer: cohort study of the common data model in the Asian population. J Clin Med. 2020;9(9):2910.
9. Shin D, Lee ES, Kim J, Guerra L, Naik D, Prida X. Association Between the Use of Thiazide Diuretics and the Risk of Skin Cancers: A Meta-Analysis of Observational Studies. J Clin Med Res. 2019;11(4):247-255.
10. Warszawik-Hendzel O, Olszewska M, Rakowska A, Sikora M, Hendzel P, Rudnicka L. Cardiovascular Drug Use and Risk of Actinic Keratosis: A Case-Control Study. Dermatol Ther (Heidelb). 2020;10(4):735-743.
11. Bigagli E, Cinci L, D’ambrosio M, Nardini P, Portelli F, Colucci R, et al. Hydrochlorothiazide Use and Risk of Nonmelanoma Skin Cancers: A Biological Plausibility Study. Oxid Med Cell Longev. 2021;2021:6655542.
12. O’neill B, Moe S, Korownyk C. Hydrochlorothiazide and squamous cell carcinoma. Can Fam Physician. 2020;66(2):116-116.
13. Drucker AM, Hollestein L, Na Y, Weinstock MA, Li WQ, Abdel Qadir HA, et al. Association between antihypertensive medications and risk of skin cancer in people older than 65 years: a population-based study. CMAJ. 2021;193(15):508-516.
14. Perdersen SA, Gaist D, Schimidt SAJ, Hölmich LR, Friis S, Pottegård A. Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark. J Am Acad Dermatol. 2018;78(4):673-681.
15. Borges JES, Camelier AA, Oliveira LVF, Brandão GS Qualidade de vida de idosos hipertensos e diabéticos da comunidade: um estudo observacional. Rev Pesqui Fisioter. 2019;9(1):74-84.
16. Dias JRP, Andrade RL, Fernandes ANM, Laurindo BM, Fonseca ERS. Análise do perfil clínico-epidemiológico dos idosos portadores de hipertensão arterial sistêmica nas microáreas 4, 6 e 7 da USF tenoné. BJHR. 2019;2(1):2-41.
17. Kim H, Ihm S, Kim G, Kim J, Kim K, Lee H, et al. Korean Society of Hypertension guidelines for the management of hypertension: part I-epidemiology of hypertension. Clin Exp Hypertens. 2019;25:1-16 – A.
18. Kim H, Ihm S, Kim G, Kim J, Kim K, Lee H, et al. Korean Society of Hypertension guidelines for the management of hypertension: part III-hypertension in special situations. Clin Exp Hypertens. 2019;25:1-16 – B.
19. Lee H, Shin J, Kim G, Park S, Ihm S, Kim H, et al. Korean Society of Hypertension Guidelines for the management of hypertension: part II-diagnosis and treatment of hypertension. Clin Exp Hypertens. 2019;25:20.
20. Kreutz R, Algharably EAH, Douros, A. Reviewing the effects of thiazide and thiazide-like diuretics as photosensitizing drugs on the risk of skin cancer. J Hypertens. 2019;37(10):1950-1958.
21. Su KA, Habel LA, Achacoso NS, Friedman GD, Agasri MM. Photosensitizing antihypertensive drug use and risk of cutaneous squamous cell carcinoma. Br J Dermatol. 2018;179(5):1088-1094.
22. Montgomery S e Scott W. Photosensitizing Drug Reactions. Clin Dermatol. 2022 Jan-Feb;40(1):57-63.
23. Mehlan J, Ueberschaar J, Hagenström K, Garbe C, Spitzer MS, Druchkiv V, Schuettauf F. The use of HCT and/or ACE inhibitors significantly increases the risk of non-melanotic skin cancer in the periocular region. Graefes Arch Clin Exp Ophthalmol. 2022;260(8):2745-2751.
24. Rouette J, Yin H, Pottegård A, Nirantharakumar K, Azoulay L. Use of Hydrochlorothiazide and Risk of Melanoma and Nonmelanoma Skin Cancer. Drug Saf. 2021;44(2):245-254.
25. Schneider R, Reinau D, Stoffel S, Jick SS, Meier CR, Spoendlin J. Risk of skin cancer in new users of thiazides and thiazide-like diuretics: a cohort study using an active comparator group. Br J Dermatol. 2021;185(2):343-352.
26. Eworuke E, Haug N, Bradley M, Cosgrove A, Zhang T, Dee EC, et al. Risk of Nonmelanoma Skin Cancer in Association With Use of Hydrochlorothiazide-Containing Products in the United States. JNCI Cancer Spectr. 2021;5(2).
27. Pottegard A, Hallas J, Olesen M, Svendsen MT, Habel LA, Friedman GD, Friis S. Hydrochlorithiazide use is strongly associated with risk of lip cancer. J Intern Med. 2017;282(4):322-331.
28. Morales DR, Pacurariu A, Slattery J, Kurz X. Association between hydrochlorothiazide exposure and different incident skin, lip and oral cavity cancers. Br J Clin Pharmacol. 2020;86(7):1336-1345.
29. Park E, Lee Y, Jue MS. Hydrochlorothiazide use and the risk of skin cancer in patients with hypertensive disorder: a nationwide retrospective cohort study from Korea. Korean J Intern Med. 2020;35(4):917-928.
30. Pottegard A, Pedersen SA, Schmidt SAJ, Lee CN, Hsu CK, Liao TC, et al. Hydrochlorithiazide use and skin cancer risk: a Taiwanese national case-control study. Br J Cancer. 2019;121(11):973-978.
Downloads
Publicado
2023-11-06
Edição
Seção
Revisão de Literatura
Licença
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Este periódico bem como seus artigos estão licenciados com a licença Creative Commons Atribuição-NãoComercial-SemDerivações 4.0 Internacional.
Como Citar
Ocorrência de carcinoma espinocelular labial não melanocítico em usuários crônicos de hidroclorotiazida. (2023). Revista Da Faculdade De Odontologia - UPF, 27(1). https://doi.org/10.5335/rfo.v27i1.14222
